Articles tagged with Parkinsons Disease
A scoping review from the University of Gothenburg found that music-based movement therapy, known as the Ronnie Gardiner Method, can improve rehabilitation outcomes in individuals with brain disorders. The method has been shown to be challenging, motivating, and enjoyable for participants, leading to improved recovery and quality of life.
A large study of female participants found no association between migraine and the development of Parkinson's disease, contrary to previous research. The study followed over 39,000 women for an average of 22 years and adjusted for various risk factors.
Researchers at UCSF have developed intelligent brain pacemakers that use AI to monitor and adjust brain activity in real-time, providing personalized treatment for Parkinson's patients. The approach, called adaptive deep brain stimulation, has shown promise in reducing symptoms such as movement problems and insomnia.
A small NIH-funded trial found an implanted device regulated by brain activity can provide continual and improved treatment for Parkinson’s disease symptoms. The study showed adaptive deep brain stimulation (aDBS) was markedly more effective at controlling PD symptoms compared to conventional DBS treatments.
A wearable sensor supported by machine learning models can continuously monitor and quantify FOG episodes, providing an accurate picture of a patient's condition. This technology has the potential to support the development of new treatments and improve the lives of people with Parkinson's disease.
Scientists at deCODE genetics have discovered rare sequence variants in ITSN1 linked to Parkinson's Disease. These variants may contribute to disease pathogenesis through CDC42 dysregulation and dopaminergic neuron degeneration.
Researchers successfully restored the brain's waste-clearing process by reviving cervical lymph vessel function in aging mice, utilizing a known drug to boost efficiency. This breakthrough could pave the way for future therapies targeting neurodegenerative diseases.
Researchers developed a technique using videos and machine learning to quantify motor symptoms in early-stage Parkinson's disease. The approach achieved high accuracy in distinguishing between healthy individuals and those with early Parkinsonism, offering potential benefits for treatment outcomes.
Researchers found that artificial induction of GluCer leads to cellular senescence in DA neurons, highlighting the role of lipid aggregation in PD. The study proposes that lysosomal impairment and lipid accumulation trigger expression of a cellular senescence phenotype in vulnerable DA neurons.
A study by researchers at São Paulo State University found that dopaminergic medication levodopa improves sleep quality in Parkinson's disease patients. The number of times patients woke up during the night fell by 25% and the amount of time they remained awake fell 30% on average.
Seoul National University researchers developed a biodegradable electronic tent technology that enables non-invasive brain disease diagnosis using a needle. The device unfolds to cover the entire brain over a large area and naturally decomposes in the body after diagnosis, minimizing side effects.
Researchers developed a new visual diagnostic technique called Cap-QuIC that can distinguish infected samples with the naked eye, enabling faster and more accurate disease detection. The method builds upon previous groundbreaking diagnostic techniques and leverages simple action to detect misfolded alpha-synuclein proteins.
Researchers at Osaka Metropolitan University found that Ecklonia cava polyphenols can protect against neurodegeneration and improve motor function in Parkinson's disease model mice. The antioxidants activate the AMPK enzyme and inhibit reactive oxygen species production, reducing neuronal cell death.
Researchers discovered elevated levels of neurofilament light chain protein in Parkinson's disease and dementia with Lewy bodies, suggesting potential early detection methods. The study found different protein patterns between the prodromal stage and established diseases.
Researchers at Brigham and Women's Hospital developed a 'Parkinson's in a dish' model that rapidly converts stem cells to brain cells with protein structures characteristic of the disease. The study enables the study of Parkinson's disease pathology in a petri dish, paving the way for personalized diagnostic and treatment methods.
The PD GENEration study has found that 13% of participants have a genetic form of Parkinson's disease, significantly higher than previous estimates. The study, which reached its goal of 15,000 participants ahead of schedule, provides insights into the genetics of the disease and its potential for precision medicine.
Researchers found that fecal microbiota transplantation did not offer significant improvements in motor and non-motor symptoms of Parkinson's disease. Further studies on modified approaches or bowel cleansing are needed to better understand the impact of donor microbiota composition.
Researchers from Tokyo Medical and Dental University demonstrate a proof of concept for antisense nucleic acid therapy to prevent the spread of α-synuclein pathologies in synucleinopathies. The treatment, involving antisense oligonucleotides, effectively reduces Lewy pathology-like neuronal inclusion by over 90%.
A new video-processing technique developed at the University of Florida uses artificial intelligence to track Parkinson's disease progression in patients, allowing neurologists to better monitor their condition and quality of life. The system analyzes video recordings of patients performing the finger-tapping test, a standard test for ...
Two proteins, NAP1 and SINTBAD, have been discovered as regulators of mitophagy in cells. This discovery opens a new area of focus for researchers targeting drug therapies to boost mitophagy activity and promote mitochondrial and neuronal health.
Researchers found a blood test to detect alpha-synuclein protein shows promise for diagnosing Parkinson's disease. The study, published in the Journal of Parkinson's Disease, confirmed that the biomarker is highly sensitive and changes over the course of the disease.
Researchers at Weill Cornell Medicine used machine learning to define three subtypes of Parkinson’s disease, each with distinct driver genes and molecular mechanisms. These subtypes may suggest customized treatment strategies for patients, potentially targeting specific drugs such as metformin to slow down progression.
Researchers created a new cortical surface template called 'OpenNeuro Average' that provides greater accuracy and efficiency in analyzing neuroimaging data. The template is based on the geometric shape of the brain and can be used for studies on cognition, clinical neuroscience, autism, and neurodegenerative diseases.
A cross-sectional study of CTE patients found that years of contact sports participation are linked to substantia nigra pathology, leading to parkinsonism. The study suggests that repetitive head impacts may trigger neuropathologic processes in individuals with CTE.
Researchers investigated the relationship between protein aggregation and liquid-liquid phase separation, finding that droplet formation may actually protect against aggregation. The study, led by Paul Scherrer Institute, used over 500 conditions to test the behavior of alpha-synuclein proteins.
A study of 481 deceased athletes found that most developed parkinsonism due to CTE pathology, not classic Parkinson's disease. Researchers identified a link between contact sport participation and severe brain cell death in the brainstem.
Researchers discovered a new genetic cause of inherited Parkinson's disease, the CARS E795V mutation, which affects protein function and leads to neurological symptoms. The study found that this rare mutation is responsible for the condition in nine individuals from four families.
A trial published in The BMJ highlights the need to optimise speech therapy resources for people with Parkinson’s disease. LSVT LOUD is more effective than conventional NHS speech and language therapy or no therapy in improving voice handicap scores.
A major clinical trial led by the University of Nottingham found that LSVT LOUD was more effective at reducing the impact of voice problems in people with Parkinson's disease compared to no speech and language therapy or NHS delivered therapy. The treatment improved communication skills, enabling participants to go out and socialize wi...
A study published in The Journal of Neuroscience found that blocking a protein called Activin A can halt dyskinesia symptoms and effectively erase the brain's 'bad memory' response to certain Parkinson's treatments. This could lead to longer-term use of L-DOPA for patients.
A study published in Radiology found that brain connectivity on MRI scans can predict the progression of brain atrophy in patients with mild Parkinson's disease. The researchers used MRI data to generate a map of the brain's neural connections, which showed potential in predicting gray matter atrophy accumulation over time.
A new study by UCL researchers found that people with anxiety over the age of 50 are at least twice as likely to develop Parkinson's disease. The study, published in the British Journal of General Practice, also identified symptoms such as depression, sleep disturbance, and fatigue as risk factors for developing the condition.
Researchers found that men taking terazosin-type medications had about a 40% lower risk of developing dementia with Lewy bodies compared to those taking tamsulosin or 5-alpha reductase inhibitors. The study suggests that these drugs may have broad potential for treating neurodegenerative conditions.
A team of researchers has developed a simple blood test that uses artificial intelligence (AI) to predict Parkinson's disease up to seven years before the onset of symptoms. The test analyzes a panel of eight blood-based biomarkers with concentrations altered in patients with Parkinson's, providing a diagnosis with 100% accuracy.
Researchers at Johns Hopkins Medicine identified a potentially new biological target involving Aplp1, which drives the spread of Parkinson's disease-causing alpha-synuclein. The findings suggest targeting this interaction with drugs could slow Parkinson's disease progression and other neurodegenerative diseases.
Dorothee Dormann and Edward Lemke propose a new concept to measure the individual risk of getting age-related diseases by analyzing protein clumps in cells. This 'protein aggregation clock' could help diagnose age-related diseases at early stages or identify people at higher risk.
Researchers found a link between gut microbiota and Parkinson's disease, revealing reduced B vitamins and intestinal barrier issues. Treatment with B vitamins could alleviate PD symptoms and slow disease progression.
Researchers at the University of Birmingham discovered a link between dopamine and mentalising abilities in healthy individuals. They found that altering dopamine levels affected participants' ability to accurately attribute mental states, with implications for treating conditions like Parkinson's disease.
Researchers have developed a study using smartwatches to monitor Parkinson's symptoms over time in early-stage patients. The study found significant declines in gait and tremor, as well as changes in speech, with the smartwatch detecting these changes more effectively than traditional tools.
Dr. Jeetain Mittal's NIH grant will support multiscale computational models investigating phase separation in biology, particularly heterochromatin formation and its role in neurodegenerative diseases. The research aims to elucidate the molecular origins of phase separation using innovative models and methods.
Researchers at University of Dundee uncovered inner relay of a molecular switch that protects the brain against Parkinson's disease. The study provides new potential strategies to develop drugs targeting PINK1 pathway.
Researchers from Mass General Brigham created an algorithm to generate personalized DBS treatment plans based on four major PD symptoms. The algorithm improved patients' symptoms in four of five cases, demonstrating its potential to improve treatment beyond standard-of-care approaches.
Patients with Parkinson's disease exhibiting sympathetic denervation in major salivary glands and the heart tend to have more advanced non-motor symptoms as they age. Autonomic nerve dysfunction may progress independently of nigrostriatal dopaminergic degeneration, suggesting a potential contribution of age to PD progression.
A study by the University of Turku found that regular caffeine consumption reduces dopamine transporter binding in Parkinson's disease patients, but has no impact on symptoms or motor function. High caffeine intake may also complicate brain imaging results, suggesting a 24-hour caffeine-free period before diagnosis is recommended.
A study led by the University of Turku has identified the brain network responsible for stuttering, which may lead to effective treatments. The research found that stuttering is associated with structural changes in a specific brain network involving the putamen, amygdala, and claustrum.
A new study at the University of Copenhagen reveals that urolithin A, a naturally occurring substance in pomegranates, can alleviate memory problems and other consequences of dementia. The substance shows promise in improving brain function by removing damaged mitochondria.
Researchers found that boosting mitochondrial health can combat protein clumping linked to both aging and Alzheimer's. The study identifies a core insoluble proteome enriched with numerous proteins not previously considered, offering new targets for exploration.
FutureNeuro, a leading SFI Research Centre, is expanding its research programme with a focus on diagnostics, therapeutics, and digital health. The centre aims to develop precision diagnostics, future treatments, and systems using real-time health data.
Researchers at Mount Sinai identified genetic connections between inflammatory bowel disease (IBD) and Parkinson’s disease (PD), highlighting potential for joint therapeutic strategies. The study found mutations in the LRRK2 gene as a common element linking both conditions, with implications for innovative treatments.
A region in alpha-synuclein protein aggregates has been identified as a potential therapeutic target to prevent conversion into toxic amyloid fibrils, which accumulate in the brains of people suffering from Parkinson's disease. The discovery opens the door to developing new therapeutic strategies for inactivating these toxic forms.
Researchers at the University of Toronto have found a way to better control the preclinical generation of key neurons depleted in Parkinson's disease. They developed an efficient method for stimulating stem cell differentiation to produce neural cells in the midbrain, which closely resemble dopaminergic neurons of natural origin.
Researchers found a shared triple network of long noncoding RNAs, microRNAs, and messenger RNAs that exacerbates Parkinson's disease symptoms in the context of COVID-19 infection. The study identified key genes and lncRNAs as potential biomarkers for PD diagnosis and progression.
A new study found that genetic variants in lysosomal genes may contribute to the development of Parkinson's disease in individuals exposed to high levels of pesticides. The research suggests a potential gene-environment interaction, where minor changes in these genes can lead to increased disease risk under stress.
Researchers found that older adults tend to conserve energy by modifying their movements under certain circumstances. The findings suggest that the effort costs of reaching are a determining factor in slowing movement with age. This research may lead to new tools for diagnosing diseases, including Parkinson's and multiple sclerosis.
Researchers from the University of Cambridge used AI to identify compounds that block alpha-synuclein aggregation, a key step in treating Parkinson's disease. This breakthrough could lead to faster development of new treatments for the condition, which affects over six million people worldwide.
Scientists at Salk Institute explore the clinical potential of cannabinol (CBN) in treating traumatic brain injury, Alzheimer's disease, and Parkinson's disease. They identify four CBN analogs with improved neuroprotective ability and drug-like efficacy.
Researchers at Van Andel Institute have identified a gene expression pattern, akin to a disease-related fingerprint, in brain cells with Lewy bodies. This finding sheds light on the molecular changes that occur in these cells, which are key pathological hallmarks of Parkinson's disease and some dementias.
Research finds Parkinson's disease alters bodily sensations associated with basic emotions, shifting focus from chest to abdominal area. The study highlights the significance of non-motor symptoms in Parkinson's disease, raising new perspectives for treatment and research.
A recent study has linked the subthalamic nucleus to attention control, revealing that this brain region also plays a role in thoughts and impulse control. The findings suggest that deep brain stimulation, used to treat Parkinson's disease, may have adverse effects on attentional processes.
Researchers from the University of Cincinnati presented findings on the effectiveness of a two-component enzyme replacement therapy for late-onset Pompe disease. The study showed that patients treated with this regimen experienced improvement or stability in motor function, pulmonary function, and muscle strength. Additionally, experts...